- NCIt
- C27674
Loading cancer entity…
Loading cancer entity…
Clinical trials
154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06508138 | Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection(J21112LINKED) | enrolling by invitation | Phase 1 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04857528 | Detecting HPV DNA in Anal and Cervical Cancers | recruiting | — | 20 | University of ChicagoOTHER |
| 1 |
| Mar 4, 2026 |
| clinicaltrials |
| NCT04988074 | Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca(MINIMA) | recruiting | Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06636734 | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05262010 | A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years | recruiting | Phase 3 | 13,500 | National Vaccine and Serum Institute, ChinaINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03215719 | Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma | recruiting | Phase 2 | 120 | NYU Langone HealthOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06756269 | To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years | recruiting | Phase 2 | 330 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06088381 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)(SAVAL) | recruiting | Phase 2 | 61 | University of Maryland, BaltimoreOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03180034 | Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study(ESCUDDO) | active not recruiting | Phase 4 | 27,945 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06307015 | De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)(DE-RADIATE) | recruiting | N/A | 25 | Royal North Shore HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06574087 | Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases. | recruiting | N/A | 248 | PCK Marine Hospital in GdyniaOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05996783 | Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial(ScreenUrSelf) | active not recruiting | N/A | 48,000 | Universiteit AntwerpenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT03061435 | Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.(Vulvar-AIN) | recruiting | N/A | 110 | Dr. Danielle VicusOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06052033 | Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection | recruiting | N/A | 40 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05829629 | Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women | recruiting | Phase 1 | 20 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06598176 | Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples(COMBISCREEN) | recruiting | N/A | 100 | Universiteit AntwerpenOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary(SUPERIOR) | not yet recruiting | Phase 2 | 90 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 3, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT05582590 | Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers | not yet recruiting | Phase 1 | 36 | NexImmune Inc.INDUSTRY | 0 | Jan 16, 2024 | clinicaltrials |
| NCT04638465 | De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma | active not recruiting | — | 150 | Nebraska Methodist Health SystemOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06041061 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years | active not recruiting | Phase 3 | 18,000 | Sinocelltech Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Mar 6, 2026source: clinicaltrials